PE20231854A1 - Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismo - Google Patents
Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismoInfo
- Publication number
- PE20231854A1 PE20231854A1 PE2023002713A PE2023002713A PE20231854A1 PE 20231854 A1 PE20231854 A1 PE 20231854A1 PE 2023002713 A PE2023002713 A PE 2023002713A PE 2023002713 A PE2023002713 A PE 2023002713A PE 20231854 A1 PE20231854 A1 PE 20231854A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referida a un anticuerpo monoclonal aislado o un fragmento de union al antigeno del mismo que se une especificamente al GD2 (gangliosido GD2), que comprende: (a) un dominio variable de la cadena pesada que comprende: CDR1 con una secuencia aminoacida seleccionada del grupo de la SEQ ID NO: 1 o SEQ ID NO: 2, CDR2 con la secuencia aminoacida de la SEQ ID NO: 3, CDR3 con una secuencia aminoacida seleccionada del grupo de la SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 o SEQ ID NO: 7; y (b) un dominio variable de la cadena ligera que comprende: (i) CDR1 con una secuencia aminoacida seleccionada del grupo de la SEQ ID NO: 8 o SEQ ID NO: 9, (ii) CDR2 con una secuencia aminoacida seleccionada del grupo de la SEQ ID NO: 10 o SEQ ID NO: 11, (iii) CDR3 con una secuencia aminoacida seleccionada del grupo de la SEQ ID NO: 12 o SEQ ID NO: 13. La invencion se refiere ademas a acidos nucleicos que codifican dicho anticuerpo, vectores de expresion, celulas huesped y metodos para producirlos, metodos para producir los anticuerpos segun la invencion, composiciones farmaceuticas que comprenden el anticuerpo segun la invencion, composiciones farmaceuticas que comprenden el anticuerpo segun la invencion y otros compuestos terapeuticamente activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021107773A RU2796937C2 (ru) | 2021-03-24 | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение | |
| PCT/RU2022/050096 WO2022203552A1 (en) | 2021-03-24 | 2022-03-24 | Monoclonal antibody that specifically binds to gd2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231854A1 true PE20231854A1 (es) | 2023-11-21 |
Family
ID=83395963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002713A PE20231854A1 (es) | 2021-03-24 | 2022-03-24 | Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismo |
Country Status (12)
| Country | Link |
|---|---|
| CN (1) | CN117677695A (es) |
| AR (1) | AR125219A1 (es) |
| CL (1) | CL2023002843A1 (es) |
| CO (1) | CO2023012549A2 (es) |
| CR (1) | CR20230456A (es) |
| EC (1) | ECSP23072412A (es) |
| MA (1) | MA62715B1 (es) |
| MX (1) | MX2023011246A (es) |
| PE (1) | PE20231854A1 (es) |
| TW (1) | TW202304989A (es) |
| UY (1) | UY39687A (es) |
| WO (1) | WO2022203552A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1706428T3 (pl) * | 2004-01-22 | 2010-02-26 | Merck Patent Gmbh | Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza |
| CA2801210C (en) * | 2010-06-19 | 2020-07-21 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| CA2903576C (en) * | 2013-03-15 | 2021-06-08 | Nai-Kong V. Cheung | High affinity anti-gd2 antibodies |
-
2022
- 2022-03-24 MA MA62715A patent/MA62715B1/fr unknown
- 2022-03-24 UY UY0001039687A patent/UY39687A/es unknown
- 2022-03-24 CR CR20230456A patent/CR20230456A/es unknown
- 2022-03-24 WO PCT/RU2022/050096 patent/WO2022203552A1/en not_active Ceased
- 2022-03-24 PE PE2023002713A patent/PE20231854A1/es unknown
- 2022-03-24 MX MX2023011246A patent/MX2023011246A/es unknown
- 2022-03-24 TW TW111111114A patent/TW202304989A/zh unknown
- 2022-03-24 CN CN202280024459.8A patent/CN117677695A/zh active Pending
- 2022-03-25 AR ARP220100720A patent/AR125219A1/es unknown
-
2023
- 2023-09-22 EC ECSENADI202372412A patent/ECSP23072412A/es unknown
- 2023-09-22 CO CONC2023/0012549A patent/CO2023012549A2/es unknown
- 2023-09-25 CL CL2023002843A patent/CL2023002843A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA62715A1 (fr) | 2024-07-31 |
| CL2023002843A1 (es) | 2024-03-22 |
| UY39687A (es) | 2022-08-31 |
| MA62715B1 (fr) | 2025-01-31 |
| AR125219A1 (es) | 2023-06-28 |
| TW202304989A (zh) | 2023-02-01 |
| WO2022203552A1 (en) | 2022-09-29 |
| CN117677695A (zh) | 2024-03-08 |
| MX2023011246A (es) | 2023-10-30 |
| CR20230456A (es) | 2023-12-13 |
| CO2023012549A2 (es) | 2023-10-09 |
| ECSP23072412A (es) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
| PE20221256A1 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| CL2021000942A1 (es) | Anticuerpos anti-npr1 y usos relacionados. | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
| PE20230384A1 (es) | Anticuerpos cd163 o proteinas de union | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| PE20230682A1 (es) | Anticuerpo anti-ox40 y usos del mismo | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| PE20240224A1 (es) | Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8 | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| PE20240369A1 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y metodos de uso de estos | |
| PE20231854A1 (es) | Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismo | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| AR130641A1 (es) | Anticuerpos anti-cd28 | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso |